CAMBRIDGE, Mass. & SAN DIEGO--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced the presentation of new data that further detail a novel, innate mechanism to allosterically modulate the N-methyl-D-aspartate (NMDA) receptor. This research, presented in three posters at the Society for Neuroscience Annual Meeting being held in San Diego, California, from November 9-13, provides SAGE with additional mechanistic understanding to further inform and accelerate drug development for a wide range of neuropsychiatric disorders, including Alzheimer’s, schizophrenia, autism and depression.
Help employers find you! Check out all the jobs and post your resume.
